Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Pfs-Clinical'
Pfs-Clinical published presentations and documents on DocSlides.
Median PFS: 2.6 months (95% CI, 1.7-3.5)
by ceila
Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...
Beyond Secret Handshakes:
by pasty-toler
Affiliation-Hiding Authenticated Key Exchange. Fr...
2014 Oklahoma Business Summit
by marina-yarberry
Sarah Roberts, Inasmuch Foundation, Program Offic...
Partnerships for Success
by test
Creating Positive School Experiences And Develop...
Ray Jones
by danika-pritchard
Director of Solutions Architecture and Field Enab...
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
Applying “Pay for Success” Social Impact Finance to Ear
by luanne-stotts
Janis Dubno, Voices for Utah Children. Andrea Phi...
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Interpretation of the Great Plains Polygonal Fault
by luanne-stotts
Andy St-Onge, Calgary geophysicist@shaw.ca. (i) S...
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
by olivia-moreira
Jointly provided by ...
Game Plan Trends in ovarian cancer
by alexa-scheidler
Diagnostic work-up. Treatment. The most commonly ...
Nouveautés dans le CBNPC métastatique
by vizettan
Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...
Presentation
by wang
pfs-full-vlSchema Taxo Fullwith capitalpfs-fullPre...
2022 Spring Oncology Conference
by byrne
Evolving Treatment Strategies. for CLL/SLL and MCL...
Update on Diagnosis and Treatments
by joanne
of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Considerations for Optimizing Transplant in Multiple Myeloma Patient Management
by TravelingSoulmate
PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
YIR On Demand Lung Benjamin Levy, MD
by jovita
Assistant Professor. Johns Hopkins School of Medic...
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref
by willow
Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...
Pay for Success: Innovative Financing to Improve Child Outcomes
by dominic513
Jennifer Tschantz; Early Childhood Research to Pra...
Company profi leProject name: Songwe Hill Rare Earths ProjectP
by min-jolicoeur
PFS well advanced, favourable topography, simple w...
Multiple Myeloma – Is It Now Curable?
by celsa-spraggs
Andrzej . J. . Jakubowiak, MD, PhD. Director, Mye...
Impact of Imatinib interruption & duration of prior Hyd
by pamella-moone
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof ...
Treatment of
by natalia-silvester
Biliary. Cancers. Abby B. Siegel, MD, MS . Colum...
Product Labels – Defending the Use of Processed Foods
by min-jolicoeur
Michigan Department of Education. School Nutritio...
Series:
by lois-ondreau
From Tax Preparer to Financial Planner: The Road ...
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
Department of GI Medical Oncology
by danika-pritchard
Does . the New EPOC trial . eliminate. . Anti. -...
Update on transplant-ineligible patients:
by trish-goza
Which . regimens are best?. Suzanne Lentzsch MD, ...
Chee Lee,
by olivia-moreira
MBBS (Hons), . MMedSci. (. Clin. . Epid. ), . M...
ASCO Update 2012:
by tatyana-admore
Gastrointestinal Malignancies. Thomas J. Semrad M...
It's Never Too Early (or Too Late) To Specialize: Is a Care
by danika-pritchard
[presenter name/business name]. [presentation dat...
Acquired Resistance Patient Forum
by test
September 6, 2014 | Boston. In ALK, ROS1 & EG...
Novel
by tatiana-dople
Agents . for . Indolent . L. ymphoma . and . Mant...
Calculating the Contribution to the Meal Pattern:
by pamella-moone
Product Formulation Statements. Webinar March 27,...
Architecture
by ellena-manuel
Rajesh. Components of Database Engine. Issue Quer...
Load More...